Golidocitinib clinical trials
Also written AZD4205.
How each study uses golidocitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the golidocitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2025 (13)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 13 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 29
Dizal Pharmaceuticals (10) · Ruijin Hospital (5) · Sun Yat-sen University (4) · Peking Union Medical College Hospital (3) · Peking University Cancer Hospital & Institute (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Fudan University (2) · Beijing Friendship Hospital (2)
Often tested with
Tested in the same studies.
Tucidinostat (6) · Zeprumetostat (2) · Immune checkpoint inhibitors (2) · Sunvozertinib (1) · SINGLE 50 (1) · Adrenal Cortex Hormones (1) · Azacitidine (1) · Selinexor (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 13, 2 in phase 3
Studies that test golidocitinib, phase 3 first.
- Jan 2027Golidocitinib Combined With Selinexor for CAEBVDPhase 2/3 · Beijing Friendship Hospital
- Nov 2027A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)Phase 3 · Dizal Pharmaceuticals
- Dec 2026Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Dec 2026Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)Phase 2 · Sun Yat-sen University
- Dec 2026Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaPhase 1/2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Golidocitinib Combined With GemOx in RR PTCLPhase 2 · Ruijin Hospital
- Mar 2027Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLCPhase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- May 2027A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCPhase 1 · Peking University Cancer Hospital & Institute
- May 2027A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLPhase 1/2 · Fudan University
- Jun 2027Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung CancerPhase 2 · The First Affiliated Hospital of Guangzhou Medical University
Studies
Open first, then newest update. How each study uses golidocitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaNot yet recruitingPhase 2Washington University School of MedicineNCT07682792Written as Golidocitinib
- A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06630091Written as Golidocitinib
- Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)RecruitingPhase 1/2Dizal PharmaceuticalsNCT07496229Written as GW5282 combined with Golidocitinib
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingPhase 1/2Peking Union Medical College HospitalNCT07754890Written as golidocitinib
- Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07753642Written as Golidocitinib
- Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung DiseaseNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07737249Written as golidocitinib plus corticosteroid
- New Genotype-guided Treatment in Newly Diagnosed PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07706959Written as Azacitidine plus Golidocitinib with CHOP
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingPhase 3Dizal PharmaceuticalsNCT07234162Written as Golidocitinib
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)RecruitingPhase 1/2Beijing Tongren HospitalNCT07525466Written as golidocitinib
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07493330Written as Zeprumetostat+Golidocitinib
- Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaRecruitingPhase 3Fudan UniversityNCT07300514Written as golidocitinib
- Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLCRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07110103Written as golidocitinib with PD-1 inhibitors
- Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line ChemotherapyRecruitingPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07414758Written as golidocitinib
- Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 2WEI XUNCT07385989Written as Golidocitinib in combination with P-GEMOX and PD-1 inhibitor
- Golidocitinib Combined With Selinexor for CAEBVDRecruitingPhase 2/3Beijing Friendship HospitalNCT07369739Written as golidocitinib
- Prospective Single-Arm Clinical Trial of GO Regimen for HLH.RecruitingPhase 2/3Beijing Friendship HospitalNCT07339345Written as Golidocitinib
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingPhase 1/2Sun Yat-sen UniversityNCT07093710Written as Golidocitinib
- Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung CancerNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT07303881Written as golidocitinib
- Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07297550Written as Golidocitinib Capsules
- Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingPhase 2Ruijin HospitalNCT07279584Written as golidocitinib
See all 39 studies that test golidocitinib →
Given beside what is tested · 3 — golidocitinib is usual care or a partner of the new treatment
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRecruitingPhase 2Ruijin HospitalNCT07380984Written as golidocitinib
- EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07339527Written as Golidocitinib
- Go-CHOP in de Novo Intestinal T-cell Lymphoma PatientsNot yet recruitingPhase 2Ruijin HospitalNCT06701344Written as Golidocitinib
Codes
What other systems call golidocitinib · ClinicalTrials.gg INT014641
- UNII (FDA) 3BY9Z3M34GGOLIDOCITINIBConfirmed FDA, Wikidata
- Wikidata Q131696536golidocitinibConfirmed FDA, Wikidata
- NCI Thesaurus C156774GolidocitinibOne source FDA
- DrugBank DB18057One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3BY9Z3M34G | GOLIDOCITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q131696536 | golidocitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156774 | Golidocitinib | One source FDA |
| DrugBank | DB18057 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.